• 1
    Ratain MJU, Golomb H, Vardiman J et al. Treatment of hairy cell leukemia with recombinant alpha-2 interferon. Blood 1985; 54: 644648.
  • 2
    Thompson JA, Brady J, Kidd P et al. Recombinant alpha-2 interferon in the treatment of hairy cell leukemia. Cancer Treat Rep 1985; 69: 791793.
  • 3
    Golomb HM, Jacobs A, Fefer A et al. Alpha-2 interferon therapy of hair cell leukemia: A multi-centered study of 64 patients. J Clin Oncol 1986; 4: 900905.
  • 4
    Jacobs AD, Champlin RE, Golde DW. Recombinant alpha-2 interferon for hairy cell leukemia. Blood 1985; 65: 10171020.
  • 5
    Ehman WC, Silber R. Recombinant alpha-2 interferon is an effective agent in the treatment of hairy cell leukemia without prior splenectomy. Am J Med 1986; 80: 11111114.
  • 6
    Huber C, Flener R, Gastl G. Interferon alpha-2c in the treatment of advanced hairy cell leukemia. Oncology 1985; (Suppl 1) 42: 79.
  • 7
    Foon KA, Sherwin SA, Abrams PG et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Eng J Med 1984; 311: 11481152.
  • 8
    Leavitt RD, Ratanatharathorn V, Ozer H et al. A phase II study of recombinant alpha-2 interferon in patients with malignant lymphoma with unfavorable histology (Abstr). Proc Amer Soc Clin Oncol 1983; 2: 54.
  • 9
    Leavitt RD, Kaplan RS, Bonnem EB et al. High and low dose treatment for high and low grade non-Hodgkin's lymphoma. Proceedings of the Second International Conference on Malignant Lymphoma. Lugano, Switzerland, June 13–15, 1984.
  • 10
    Wagstaff J, Crowther D. Human alpha-2 interferon (SCH 30500) in the non-Hodgkin's lymphomas (NHL): A report of 2 phase II studies. Br J Can 1984; 50: 244.
  • 11
    Costanzi JJ, Cooper MR, Scarffee JH et al. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol 1985; 3: 654659.
  • 12
    Niederle N, Doberaver C, Kloke O et al. Treatment of chronic myelogenous leukemia with recombinant interferon alpha (IFN-alpha 2B) (Abstr). Proc Am Soc Clin Oncol 1986; 5: 236.
  • 13
    Niaderls N, Kloke C, Doberaver C et al. Alpha-2 interferon: Erste Behandlungsergebnisse bei den chronischen myeloischen Leukämie. Dtsch Med Wochenschr 1986; 111: 767771.
  • 14
    Talpaz M, Kantarjian HM, McCredie K et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha-2 in chronic myelogenous leukemia. N Eng J Med 1986; 314: 10651069.
  • 15
    Bergsagel DE, Haas RM, Messner HA. Interferon Alfa-2b in the treatment of chronic granulocytic leukemia. Semin Oncol 1986; (Suppl 2) 13: 2934.
  • 16
    Foon KA, Roth MS, Bunn DA. Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia. Semin Oncol 1986; (Suppl 2) 13: 3542.
  • 17
    Ochs J, Abramowitch M, Rudnick S et al. Phase I/II study of recombinant alpha-2 interferon against advanced leukemia and lymphoma in children. J Clin Oncol 1986; 4: 883887.
  • 18
    Faltynek CR, Princler GL, Rossio JL et al. Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases. Blood 1986; 67: 10771082.
  • 19
    Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ. Treatment of Kaposi's sarcoma with alfa-2b interferon (Intron-A). Cancer 1987; 59: 620625.
  • 20
    Abrams DI and Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol 1986; (Suppl 2) 13: 4347.
  • 21
    Real FX, Oettgon HF, Krown SE. Kaposi's sarcoma and the acquired immunodeficiency syndrome: Treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986; 4: 544551.
  • 22
    Yamamoto JK, Barre-Sinoussi F, Bulton V et al. Human alpha- and beta-interferon but not gamma suppress the in vitro replication of LAY, HTLV III, and ARV-2. J Interferon Res 1986; 6: 143152.
  • 23
    Silgals RM, Ahlgren JD, Neefe JR. A phase II trial of high dose intravenous interferon alpha-2 in advanced colorectal cancer. Cancer 1984; 54: 22572261.
  • 24
    Wasserman J, Lundell G, Blomgren H et al. Treatment of patients with disseminated colorectal cancer with recombinant human alpha-2 interferon: Studies on the immune system. Int J Cancer 1984; 33: 251256.
  • 25
    Muss HB, Kempf RA, Martino S et al. A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer. J Clin Oncol 1984; 2: 10121016.
  • 26
    Balkwill FR, Bodmer J, Rubens RD. Recombinant DNA human interferon alpha-2 (IFN) in advanced breast cancer (ABC). Br J Cancer 1984; 49: 390.
  • 27
    Niederle N, Kurschel E, Schmidt CG. Biologic effects of recombinant leukocyte alpha-2 interferon in metastatic carcinomas. Dtsch Med Wochenschr 1984; 109: 779782.
  • 28
    Muss HB, Costanzi JJ, Leavitt R et al. Recombinant alfa interferon in route cell carcinoma: A randomized trial of two routes of administration. J Clin Oncol (in press).
  • 29
    Kirkwood JM, Ernstoff M. Melanoma: Therapeutic options with recombinant interferon. Semin Oncol 1985; (Suppl 5) 12: 712.
  • 30
    Welander CE, Morgan TM, Homesley MD et al. Combined recombinant interferon alpha-2 and cytotoxic agents studied in clonogenic assay. Int J Cancer 1985; 35: 721729.
  • 31
    Von Hoff DD, Sarosy G, Brown TD et al. Rationale for and conduct of a Phase I clinical trial with interferon alfa-2b plus doxorubicin. Semin Oncol 1986; (Suppl 2) 13: 7277.
  • 32
    Durie BGM, Clouse L, Braich T et al. Interferon alfa-2b cyclophosphamide combination studies: In vitro and Phase I-II clinical results. Semin Oncol 1986; (Suppl 2) 13: 8488.
  • 33
    Berek JS, Hacker NF, Lichtenstein A et al. Intraperitoneal recombinant alpha interferon for “salvage” immunotherapy in stage II epithelial ovarian cancer: A gynecologic oncology group study. Cancer Res 1985; 45: 44474453.
  • 34
    Torti FM, Shortliffe LD, Williams RD et al. Superficial bladder cancers are responsive to alpha-2 interferon administration intravesically (Abstr). Proc Am Soc Clin Oncol 1984; 3: 160.
  • 35
    Spiegel RJ. Intron A® (interferon alfa-2b): Clinical overview and future directions. Semin Oncol 1986; (Suppl 2) 13: 89101.
  • 36
    Vallbracht A, Treuner J, Flehmig B et al. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 1981; 299: 496497.
  • 37
    Trown PW, Kramer MJ, Dennin RA et al. Antibodies to human leukocyte interferon in cancer patients. Lancet 1983; 1: 8184.
  • 38
    Gutterman JU, Seymour F, Quesada J et al. Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance and biologic effects in cancer patients. Ann Intern Med 1982; 96: 549556.
  • 39
    Krown SE, Real FX, Cunningham-Rundles S et al. Preliminary observation on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983; 308: 10711076.
  • 40
    Quesada JR, Hawkins M, Horning S et al. Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med 1984; 77: 427432.
  • 41
    Quesada JR, Rios A, Swanson D et al. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985; 3: 15221528.
  • 42
    Quesada JR, Gutterman JU. Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in an intermittent schedule in cancer patients. JNCI 1983; 70: 10411046.
  • 43
    Shah I, Band J, Rudnick S. Pharmacokinetics and tolerance of intravenous recombinant alpha-2 interferon (alpha-2 IFN) in patients with lymphoproliferative malignancies (abstr). Clin Res 1982; 30: 732A.
  • 44
    Edelstein MB, Schellekens H, Laurent T, Gauci L. A phase I clinical tolerance study of rDNA alpha-2 human interferon in patients with non-reticuloendothelial system malignancies. Eur J Cancer 1983; 19: 891894.
  • 45
    Bretaudeau B, Palangie T, Giralt E et al. Phase I trial of tolerance to increasing doses of recombinant DNA human alpha interferon in patients with advanced cancer. Cancer 1984; 71: 4049.
  • 46
    Muss HB, Kempf RA, Martino S et al. A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer. J Clin Oncol 1984; 2: 10121016.
  • 47
    Jones GJ, Itri LM. Safety and tolerance of recombinant alfa-2b (Roferon-A) in cancer patients. Cancer 1986; (Suppl) 57: 17091715.
  • 48
    Schmidt H, Heidmann E, Vallbracht A, Waller HD. Antibodies to human leukocyte interferon alpha after half a year of interferon treatment. Tumor Diag Ther 1985; 6: 3741.
  • 49
    Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron-A). Am J Med 1986; 80: 223227.
  • 50
    Protzman WP, Jacobs SL, Minnicozzi M et al. A radioimmunologic technique to screen for antibody to alpha-2 interferon. J Immunol Methods 1984; 75: 317323.
  • 51
    Yeh TJ, McBride PJ, Overall JC, Green JA. Automated quantitative cytopathic effect reduction assay for interferon. J Clin Microbiol 1982; 16: 413.